Neuroquantix

NeuroQuantix is a Digitized Archimedes Spiral Drawing Test (DAST) that leverages state-of-the-art, easy to deploy technology withinin a regulatory adhering framework.  The DAST is a simple to perform drawing task, that leverages multimodal sensor arrays to produce 100+ metrics. 

Primary Symptoms Measured:

• Tremor
• Ataxia
• Dystonia
• Rigidity
• Dyskinesia

Primary Disorders:

• Parkinson's Disease
• Essential Tremor
• Various Ataxias 
• Various Dystonic Disorders

 It can be used as an:

• Efficacy Endpoint (Secondary or Exploratory)
• Enrichment Tool
• Screening Device
• Data Quality Monitoring System

Depending on the context, NeuroQuantix could be referred to as an Efficacy Endpoint, COA, PerfO, DHT, Digital Biomarker,  

NeuroQuantix drastically reduces rater bias inherent in traditional endpoints.  The enhanced precision over traditional methods such as the UPDRS, allows the device to improve statistical power, resulting in a higher probability of treatment effect detection or a reduced sample size requirement (n). 

As such, it is ideal for preliminary efficacy data in a Phase I study or for fine motor claims in Phase II/III studies.  

NeuroQuantix can be used both in-clinic and as a remote tool for Decentralized Clinical Trials.  Cerebral Innovations provides training for both scenarios. 

NeuroQuantix can increase both the efficiency and accuracy of inclusion criteria. For example,  a brief session could be performed by a research coordinator to provide discriminatory evidence between Essential Tremor and Parkinson's Disease.  Many solutions exist and are project specific. 

NeuroQuantix  can enrich clinical trials by prospectively identifying and selecting patient subgroups based on quantifiable motor characteristics, such as tremor severity or patterns, thus increasing the likelihood of detecting a treatment effect in a targeted population. Enrichment solutions are project-specific based on sponsor requirements. 

We have a full software development team and are willing to tailor our product and services to your clinical program needs. 

DAST has been or can be used in the following diseases/disorders: 

• Parkinson’s Disease (Early and Advanced Stages)
• Essential Tremor 
• Spinocerebellar Ataxia
• Friedrich’s Ataxia 
• Dystonic Disorders, including Focal Hand Dystonia, Cervical Dystonia, Generalized Dystonia
• Multiple Sclerosis
• Atypical Parkinsonisms (e.g., early Multiple System Atrophy, Progressive Supranuclear Palsy)
• Huntington’s Disease
• Wilson’s Disease
• Niemann-Pick Disease Type C
• Galactosemia
• Post-Stroke Motor Deficits
• Drug-Induced Movement Disorders (e.g., Lithium-Associated Tremors)
• Alzheimer’s Disease with Motor Features